FibroBiologics, Inc. Common Stock
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FBLG research report →
Range $180 – $180
Price Chart
About the company
FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair.
- CEO
- Peter O'Heeron
- IPO
- 2024
- Employees
- 15
- HQ
- Houston, TX, US
Get TickerSpark's AI analysis on FBLG
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.37M
- P/E
- -0.19
- PEG
- 0.27
- P/S
- 0.00
- P/B
- 0.92
- EV/EBITDA
- -0.02
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -536.78%
- ROIC
- -274.34%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-832,000+0.0%
- Op Income
- $-16,649,000
- Net Income
- $-18,646,000-67.1%
- EPS
- $-8.35-22.8%
- OCF Growth
- -37.8%
- FCF Growth
- -37.8%
- 52W High
- $11.40
- 52W Low
- $0.62
- 50D MA
- $1.28
- 200D MA
- $2.82
- Beta
- 1.22
- RSI (14)
- 36
- Avg Volume
- 199.04K
No earnings-call transcripts are available for FBLG yet.
- Free Float
- 76.5%
- Shares Outstanding
- 2.10M
- Float Shares
- 1.60M
of shares held by institutions
17 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 1.22M | ▼ 17.44K |
| Cascade Financial Partners, LLC | 108.83K | ▲ 92.40K |
| Fund Evaluation Group, LLC | 51.79K | 0 |
| Geode Capital Management, LLC | 30.30K | ▲ 690 |
| Vanguard Capital Management LLC | 27.77K | ▼ 39.90K |
| Qube Research & Technologies Ltd | 24.31K | ▲ 24.31K |
| Blackrock, Inc. | 18.24K | ▼ 6.41K |
| Barclays PLC | 7.24K | ▲ 7.24K |
| Vanguard Fiduciary Trust Co | 6.38K | 0 |
| Tower Research Capital LLC (Trc) | 4.73K | ▲ 4.27K |
| Advisor Group Holdings, Inc. | 2.40K | ▲ 2.25K |
| Royal Bank Of Canada | 1.52K | ▲ 1.52K |
Held by 7 ETFs
Biggest fund positions in FBLG by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 15, 26 | Khoja Hamid | other | 298,508 |
| Sep 15, 26 | Khoja Hamid | other | 298,508 |
| Aug 20, 26 | Steinberg Leigh | other | 0 |
| Jul 8, 26 | Rubins Kathleen Hallisey | other | 562 |
| Jun 23, 26 | Hoffman Robert E. | other | 30,803 |
| Jun 23, 26 | Cilento Richard C. Jr. | other | 30,803 |
| Jun 23, 26 | Link Matthew | other | 30,803 |
| Jun 23, 26 | Niklas Victoria Ninon Olivia | other | 30,803 |
| May 4, 26 | O'HEERON PETE | other | 92,410 |
| May 4, 26 | Khoja Hamid | other | 61,607 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our FBLG coverage
Recent articles, reports, and earnings notes.
No research on FBLG yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate FBLG report →FibroBiologics Announces Grant of European Patent for Methods of Enhancing Fibroblast Therapeutic Activity
prnewswire.com · Sep 29
FibroBiologics, Inc. (FBLG) Discusses Strategy and Clinical Progress in Fibroblast-Based Cell Therapies for Chronic Diseases Transcript
seekingalpha.com · Sep 22
FibroBiologics Announces Closing of $0.5 Million Private Placement with Chief Scientific Officer
prnewswire.com · Sep 17
FibroBiologics Announces Issuance of New U.S. Patent for the Therapeutic Use of Fibroblasts in Wound Healing
prnewswire.com · Sep 3
FibroBiologics Announces Issuance of New U.S. Patent for the Treatment of Degenerative Disc Disease Using Fibroblast Conditioned Media
prnewswire.com · Sep 1
FibroBiologics advances diabetic ulcer trial with new drug shipment to Australia
proactiveinvestors.co.uk · Aug 27
FibroBiologics Releases Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
prnewswire.com · Aug 27
FibroBiologics Regains Compliance with Nasdaq Trading Rules
prnewswire.com · Aug 26
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.